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EXPERIMENTAL STUDY 
Abstract 
Objectives 
To evaluate the cross protection conferred by pooled anti-lipopolysaccharide antibodies in 
human sera against a challenge with a specific lipopolysaccharide (LPS) endotoxin. 
Methods 
Three groups, each comprising of fifteen weight and sex matched Tuck-ordinary  (T.O) mice 
were passively immunized intraperitoneally with 0.25 ml of 0.15M sterile PBS saline, 0.25 ml 
of high titer J5 (mutant E.coli 0111:B4) LPS antiserum, and 0.25 ml of high titer concoction LPS 
antiserum containing a mixture of antibodies against four different endotoxins. After one 
hour all mice received intraperitoneal injection of 5 Ǎg (LD-100) LPS from Salmonella abortus 
equii in sterile PBS containing 10 mg D-galactosamine. Survival of mice was assessed at four 
hourly intervals for 24 hours. Mice surviving 24 hours after administration of LPS were 
considered as protected.  
Conclusion 
Concoction LPS antiserum was able to provide 100% protection since all the mice in that 
group survived at the end of 24 hours. E.coli J5-LPS antiserum could protect only nine out of 
fifteen mice (60%), whereas none of the mice survived in the group that received normal 
saline (p0.0001, ǘ2 =30.53).  
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Introduction 
nfections caused by gram negative 
bacteria constitute one of the major causes 
of the sepsis syndrome, characterized by 
hypotension, tachycardia, tachypnea, 
disseminated intra vascular coagulation, 
and multiple organ system failure P1P. Gram-
negative bacterial sepsis is a serious 
complication especially in patients with 
burns, trauma and post-operative cases of 
abdominal surgery in intensive care units. 
Although antibiotic therapy plays an 
important role in limiting the incidence of 
this complication, there has been a little 
change in the mortality of this condition 
once developed P2P. The mortality rate for 
septic shock patients continues to be 
unacceptably high, in spite of the 
therapeutic intervention and rigorous 
supportive careP 3, 4P.  
It is generally acknowledged that the 
systemic inflammatory response associated 
with gram-negative bacterial infection is 
triggered by the release of 
lipopolysaccharide (LPS) from bacterial cell 
wallP5P. LPS is the main component of the 
outer membrane of the cell wall of gram-
negative bacteria and is believed to be 
responsible for the initiation of endotoxic 
shock. The systemic administration of LPS 
has been commonly used in experimental 
animals to reproduce the typical feature of 
clinical septic shock, including the 
production      of                pro-inflammatory  
mediatorsP6,7 P. P PTherefore this molecule has 
been targeted for development of new 
preventive and therapeutic strategy P8P.  
It has been found that endotoxins derived 
from different bacterial species share a 
common basic structure P9P. LPS consists of a 
polysaccharide part that includes an O-
specific chain and core oligosacchride (OS) 
linked in a covalent bond to lipid AP10P.  
Most of the antibodies produced during 
immunization with bacterial cells are 
directed against the O-specific part of 
endotoxin. The variability of O-sero-types 
among bacteria of one species prevents the 
use of anti-LPS antibodies as broad-
protective agents for therapeutic 
intervention in gram negative bacterial 
infections. The core oligosaccharide is a 
conserved part of endotoxins. Structural 
analysis of LPS isolated from different 
strains of bacteria show less variability 
among the core oligosaccharide part in 
comparison with o-specific chain P11P. 
In order to address the issue, this study was 
performed to evaluate cross protection 
conferred by antibodies against LPS from 
E.coli J5 rough core oligosaccharide and 
against LPSs from a concoction of four 
different gram negative bacteria (E.coli 
EH100, Salmonella minnesota Re595, 
Salmonella typhimurium SL684 and Shigella 
flexneri).   
 
Materials and Methods 
UScreening for High Titer Human Antisera 
Antisera were obtained from the routine 
blood samples sent to the laboratory for 
other investigations. All the sera were 
screened for E.coli J5 LPS and the concoction 
LPS antibodies using enzyme-linked 
immunosorbent assay (ELISA) technique P12P. 
Briefly, ELISA plates (Immulon M129, 
Dynatech) were coated with 20 Ǎg/ml of 
either E.coli 0111:B4 J5 mutant Rc chemotype 
LPS at 1mg/ml in pyrogen free water or 
E.coli EH100, Salmonella minnesota Re595, 
Salmonella typhimurium SL684 and Shigella 
flexneri were diluted 1mg/ml in pyrogen 
free water and used as a combination of LPS 
(Sigma) overnight at room temperature. The 
plates were incubated for 1 hour with 1% 
pyrogen-free BSA at 37 to block nonspecific 
binding and washed three times with 
washing buffer (0.1% Tween20 containing 
0.05 % Sodium azide and 0.02M Magnesium 
Chloride (MgCl). Following this, 100 Ǎl of 
test sera were dispensed in the in micro-titer 
plate and incubated (1 hour at 37 ÝC). Plates 
were then washed five times in washing 
buffer then 100 Ǎl alkaline phosphatase 
conjugate anti human IgG was added to 
plates and incubated (1 hour at 37 ÝC). At 
the end of incubation period the plates were 
washed five times with washing buffer. 
Finally, alkaline phosphatase substrate 
(Sigma) was added to all the wells and 
optical density was obtained using 405nm 
I 
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filter. Sera containing IgG to E.coli J5 LPS 
and the cocktail LPS either equal to or more 
than a titer of 1:2560 were collected and 
used in the experiment. 
 
Mouse Protection Studies 
Three groups of fifteen Tuck Ordinary (T.O) 
mice each matched for weight, age and sex 
(Harlan Olac, UK) were used in the study. 
Each group of mice received an 
intraperitoneal injection of either 0.25 ml of 
0.15M sterile PBS, 0.25 ml (dose calculated 
earlier by series of titration) of high titer anti 
J5 serum or 0.25 ml of high titer anti 
concoction serum. An hour later, all mice 
were injected intraperitonially with a lethal 
dose of 5 Ǎg of commercially obtained pure 
LPS (Sigma product, UK) from Salmonella 
abortus equii in sterile PBS containing 10 mg 
D-galactosamine lethal dose (LD100) in 24 
hours. This dose was determined prior to 
experimenting on mice through series of 
dilutions. Mice were kept in separate cages 
and examined at four hourly intervals. Mice 
surviving 24 hours after administration of 
LPS were considered protected. Statistical 
significance was assessed by Chi square test. 
Results 
Figure 1 shows the result of protection 
conferred by anti LPS sera against septic 
shock inflicted by the lethal dose challenge 
with Salmonella abortus equii. Over 24-hour 
period, none of the mice survived the 
challenge in the group immunized by PBS 
saline. Pooled human anti E.coli J5 sera, 
however, provided 60% protection (out of 15 
mice 9 survived). On the other hand, pooled 
human anti concoction serum provided 
100% protection (p<0.0001, ǘ2 =30.53), where 
all the 15 mice had survived 24 hours after 
the challenge with Salmonella abortus equii 
LPS (Table 1). 
 
 
 
Figure 1: Survival chart for mice illustrating cross protection conferred by anti-LPS Sera
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Table 1:  Survival of mice given 0.25 ml anti-J5 sera, anti-concoction sera or 0.25 ml saline 60 
minute before an LD-100 injection of LPS from Salmonella abortus equii 
Antisera Number Surviving Mice After 24 Hrs N(%) 
Anti-J5* 15 9 (60%) 
Anti-
concoction** 
 
15 
 
 
15 (100%) 
 
 
Saline 
 
15 0 (0%) 
* Mutant Escherichia coli 0111: B4 J5-Rc chemotype LPS. 
** (E.coli EH100, Salmonella Minnesota Re595, Salmonella typhimurium SL 684 and Shigella flexneri) 
mixture LPSs. 
 
Discussion 
 
This study shows that anti concoction LPS 
serum effectively provides protection 
against gram negative septic syndrome, 
whereas the anti E.coli J5 serum provided a 
less efficient protection. The idea of 
targeting rough mutant antibodies as 
broadly cross protective therapy gained 
popularity with the report that equine 
antiserum raised against Salmonella strain of 
the Ra chemo type protected mice against 
challenge with virulent strain of Klebsiella 
pneumoniae 13. However, due to the fact that 
immunodominant epitope in E.coli J5 (Rc) 
chemotype is the most conserved among 
gram negative organisms, it has been used 
in most investigations of cross protection by 
rough mutant organism 14. 
Passive immunization with J5 was reported 
to provide partial protection to experimental 
animals against toxic effects of LPS 15-18 .The 
same partial protection was reported against 
lethal gram negative bacteremia19, 20. 
Previous animal model studies conducted 
on a large scale showed that E.coli J5 
antiserum could offer only 56-59% 
protection15, 21.  
Although a small number of mice were used 
in this study the protection offered by E.coli-
J5 antibodies was similar (60%), suggesting 
that antiserum comprising of IgG against a 
single organism LPS provides partial cross 
protection against gram negative sepsis.  
Since the sharing of bacterial antigens across 
the species is a well known phenomenon 
and in order to increase achieved cross 
protection using antisera, it would appear 
logical to use antiserum that contains 
immunoglobulins against LPS from more 
than one organism11. A pervious study 
using the antisera comprising of 
immunoglobulins against two organisms 
failed to show any enhancement in the 
protection of animals against gram negative 
sepsis22. These finding are in contradiction 
to what was observed in the present study, 
where a concoction of immunoglobulins 
against four different organisms proved to 
be more effective compared to the antisera 
containing IgGs against a single organism. 
The difference could be due to the fact that 
the anti serum used in the previous 
studies18,22 was derived from animal source 
whereas the antiserum used in the present 
study was of human origin. The difference 
in the ability of human and animal immune 
response to react to foreign antigens may be 
responsible for the discrepancy of results 
observed in the studies.   
 Despite some contradictions in previous 
experimental findings, there is evidence that 
anti core antibodies protect in clinical 
settings, as illustrated in recent studies 
which show that high levels of natural anti-
LPS core antibodies correlate with reduced 
incidence of complications after surgery and 
better outcomes from infection23 – 25. 
Human antisera against septic shock caused by endotoxins 
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 In the study using concoction LPS was 
shown to confer complete cross-protection 
against lethal challenge with LPS. Despite of 
the fact that the concoction LPS did not 
contain anti LPS antibodies specific to the 
LPS used for the lethal challenge, the 
concoction LPS appeared to have the ability 
to protect the mice efficiently. Because of 
shared antigens among different gram 
negative LPS further studies are needed to 
elucidate the role of pooled human anti sera 
containing anti LPS antibodies against 
various organisms as a potential therapeutic 
agent. The fact that the anti human sera 
used in this study was collected from blood 
specimens would open a new venue in mass 
screening of blood donors for the presence 
of relevant protective antibodies that could 
provide effective protection in septic shock 
syndrome. Recent study has demonstrated 
that the cyanobacterial LPS analogue, CyP, 
has inhibited E.coli LPS-induced cytokines 
as an inflammatory agent26.  
Other studies have illustrated that a 
combined inhibition of complement and 
CD14 abolish E.coli-induced inflammatory 
response in human blood7, 27. On the other 
hand, some have argued that the 
cooperative interplay between the LPS-
binding protein (LBP), the membrane-bound 
of CD14 and TLRs are required to trigger a 
pro-inflammatory response which is crucial 
for keeping infection under control28.   
Finally, a combination therapy of anti 
bacterial drugs, anti concoction LPS and 
anti-inflammatory agents might be 
suggested for optimal treatment to 
overcome the complexity of sepsis. 
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